ALXO — ALX Oncology Holdings Share News
0.000.00%
Last trade - 00:00ALX Oncology Holdings Inc expected to post a loss of 15 cents a share - Earnings Preview
ALX Oncology Q2 net loss narrows on lower R&D costs
Brief: ALX Oncology Q2 Basic EPS USD -0.13
Brief: Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing
ALX Oncologys' Q1 loss narrows on lower expenses
Brief: ALX Oncology Q1 Basic EPS USD -0.17
Brief: Alx Oncology’S Evorpacept In Combination With Zanidatamab Generates Promising, Durable Response In Patients With Advanced Her2-Positive Breast Cancer And High Cd47 Expression
Brief: Alx Oncology Reports Inducement Grant As Permitted By The Nasdaq Listing Rules
ALX Oncology Q4 loss narrows, names permanent CMO
Brief: ALX Oncology Q4 Basic EPS USD -0.42
U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
U.S. STOCKS ON THE MOVE-Charter Communications, Western Digital, Regeneron
U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology
ALX Oncology rises as early breast cancer trial shows promise
ALX Oncology Q3 net loss narrows as R&D costs drop
ALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
ALX Oncology Holdings Inc expected to post a loss of 45 cents a share - Earnings Preview
ALX Oncology Holdings Inc expected to post a loss of 45 cents a share - Earnings Preview
ALX Oncology Holdings Inc reports results for the quarter ended March 31 - Earnings Summary